Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29325188 | 0.94 | CYP3A4 (0.55) | ADORA2ACYP3A4CYP2C9ADORA3P2RY12 | |
| SCHEMBL26810481 | 0.94 | CYP3A4 (0.55) | ADORA2ACYP3A4CYP2C9ADORA3P2RY12 | |
| SCHEMBL29323356 | 0.94 | CYP3A4 (0.55) | ADORA2ACYP3A4CYP2C9ADORA3P2RY12 | |
| SCHEMBL26810500 | 0.94 | CYP3A4 (0.55) | ADORA2ACYP3A4CYP2C9ADORA3P2RY12 | |
| SCHEMBL29325179 | 0.94 | CYP3A4 (0.55) | ADORA2ACYP3A4CYP2C9ADORA3P2RY12 | |
| SCHEMBL3485904 | 0.92 | CYP3A4 (0.57) | ADORA2ACYP3A4CYP2C9P2RY12NT5E | |
| SCHEMBL16174662 | 0.92 | CYP3A4 (0.57) | ADORA2ACYP3A4CYP2C9P2RY12NT5E | |
| SCHEMBL14367302 | 0.89 | CYP3A4 (0.51) | CYP3A4CYP2C9 | |
| SCHEMBL16080921 | 0.88 | CYP3A4 (0.56) | ADORA2ACYP3A4CYP2C9P2RY12 | |
| SCHEMBL16080959 | 0.88 | CYP3A4 (0.56) | ADORA2ACYP3A4CYP2C9P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773355-B1 | NUCLEOSIDE ARYL PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20070265222-A1 | Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection | MERCK SHARP & DOHME CORP. | 2007-11-15 | — | — | US | disclosed |
| US-20070265222-A1 | Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection | MERCK SHARP & DOHME CORP. | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265222-A1 | Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection | NSUN3, NSUN2, PNP | ADORA2A 395/4885CYP3A4 1517/4885CYP2C9 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.